Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18 and 70 years~* For women, effective contraception during the trial and a negative pregnancy test (urine) before enrollment~* Patients naïve to prior hepatitis C treatment~* Confirmed HCV infection, based on the presence of HCV antibodies and plasma viremia allowing a measure of the circulating viral load~* Infection with HCV genotype 1 or 4~* Intent of treatment Alfa2 pegylated IFN-/ ribavirin~Exclusion Criteria:~* HBV Infection~* HIV Infection~* Severe anemia (Hb \<7-8 g / dl)~* Renal failure (creatinine clearance \<60 ml / min)~* Taking digoxin within 6 months of starting treatment.~* Taking immunosuppressants within 6 months of starting treatment~* History of serious hypersensitivity reaction (such as anaphylactic shock or angioedema) to sitagliptin~* Patients with type I and II diabetes~* Pregnancy or absence of effective contraception~* A person deprived of liberty by judicial or administrative decision~* Living conditions-suggesting an inability to track all scheduled visits by the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- DPPIV Inhibition (Type: EXPERIMENTAL): The study includes an initial phase of 3 weeks with administration of sitagliptin (100 mg/d) as monotherapy, followed immediately by 12 weeks of triple therapy (sitagliptin 100 mg/d combined with peg-IFN alfa-2a and ribavirin).

Based on this trial design, predict the completion outcome and termination type (if applicable).